romurtide and Hyperplasia

The chronic toxicity of N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L-18), muroctasin), a synthetic muramyl dipeptide, was investigated in mice. Leukocytosis and immunologically activated appearances of splenic white pulp and lung were seen in mice, when treated with MDP-Lys(L18) for 26 weeks. Furthermore, inflammation around the injection site and synovial epithelium hyperplasia of the tarsal joint occurred in higher incidence in the high dose group. These changes were similar to those seen in the subacute toxicity study with mice.

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Female; Hyperplasia; Inflammation; Leukocytosis; Lung; Male; Mice; Organ Size; Spleen

The subacute toxicity of N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys (L18), muroctasin), a synthetic muramyl dipeptide, was investigated in mice and dogs. Both species exhibited leukocytosis, immunologically activated appearances of the axillary lymphnode and splenic white pulp, and irritatic lesions at the injection site, when treated with MDP-Lys(L18) for 4 weeks. Anemia, and synovitis were also found in dogs. These findings reflected main pharmacological action of MDP-Lys(L18), though there was some species difference.

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Anemia; Animals; Dogs; Female; Hyperplasia; Leukocytosis; Lymph Nodes; Male; Mice; Motor Activity; Organ Size; Spleen; Synovitis